Episode Summary
This episode examines the World Health Organization's groundbreaking guidance on novel snakebite treatments, addressing snakebite envenoming as a critical neglected tropical disease affecting 5.4 million people annually. The WHO's new Target Product Profiles (TPPs) establish standards for innovative therapeutics, including small-molecule drugs and engineered antibody therapies, designed to improve survival outcomes and reduce disability among vulnerable populations in rural and resource-limited settings worldwide.
Key Topics Discussed
- Snakebite envenoming epidemiology and global disease burden, with 83,000-138,000 deaths annually
- Limitations of conventional antivenoms derived from animal plasma and the need for accessible alternatives
- WHO Target Product Profiles (TPPs) for next-generation snakebite therapeutics and innovation in treatment development
- Hospital-based and pre-hospital treatment approaches for stabilizing snakebite victims in remote communities
- Access barriers to effective snakebite treatment in low-resource and underserved rural regions
- WHO's 2030 global strategy for reducing snakebite mortality and disability among at-risk populations
Key Takeaways
- Snakebite envenoming represents a neglected tropical disease with significant yet preventable mortality and morbidity burden globally
- Novel therapeutics such as engineered antibodies and small-molecule drugs offer safer, more affordable, and more accessible alternatives to traditional animal-derived antivenoms
- Dual treatment strategies combining pre-hospital stabilization with hospital-based interventions can significantly improve outcomes in resource-limited settings
- WHO guidance provides evidence-based standards for therapeutic development prioritizing efficacy, safety, and accessibility for vulnerable populations
- Addressing snakebite as a public health priority requires coordinated innovation in pharmaceutical development and healthcare delivery infrastructure
About This Episode
Snakebite envenoming remains a critical yet underrecognized global health challenge, particularly affecting rural communities in low- and middle-income countries. This episode's discussion of WHO's Target Product Profiles is essential for clinicians, public health officials, and healthcare policymakers involved in tropical medicine and global health strategy. The guidance represents a pivotal shift toward evidence-based therapeutic innovation, addressing treatment gaps that disproportionately impact underserved populations. Understanding these developments is vital for healthcare systems strengthening in regions with high snakebite burden, including parts of the Caucasus region and beyond.
In this episode of the GMJ Podcast — the official podcast of the Georgian Medical Journal, we examine new guidance from the World Health Organization on the development of novel treatments for snakebite envenoming, a neglected tropical disease that continues to cause major health impacts worldwide.
Snakebites affect an estimated 5.4 million people each year, leading to 83,000 to 138,000 deaths and leaving hundreds of thousands of survivors with permanent disabilities. Many of these cases occur in rural and low-resource settings where access to effective treatment remains limited.
To address these challenges, WHO has published the first Target Product Profiles (TPPs) for innovative snakebite therapeutics. These profiles define the minimum and optimal characteristics that new treatments should meet in order to be safe, effective and accessible for populations most at risk.
Unlike traditional antivenoms derived from animal plasma, the new guidance focuses on novel approaches such as small-molecule drugs and engineered antibody therapies that could potentially offer safer, more affordable and easier-to-administer treatment options.
WHO proposes two key types of future therapeutics:
• Hospital-based treatments, potentially used alongside conventional antivenoms
• Pre-hospital treatments, designed to stabilize patients immediately after a snakebite and “buy time” until medical care is available
These innovations could significantly improve survival and reduce long-term disability among snakebite victims, particularly in remote communities where rapid access to hospitals is difficult.
The episode explores several key global health issues:
• Snakebite envenoming as a neglected tropical disease
• Limitations of current antivenom therapies
• The role of innovation in developing next-generation treatments
• Improving access to treatment in rural and underserved regions
• WHO’s global strategy to reduce snakebite deaths and disabilities by 2030
The WHO emphasizes that developing safer and more accessible snakebite treatments is essential to address one of the most neglected yet deadly health threats affecting rural populations worldwide.
Original WHO source discussed in this episode:
https://www.who.int/news/item/27-02-2026-new-who-guidance-on-novel-snakebite-treatments-published
The GMJ Podcast accompanies peer-reviewed publications and global health policy discussions published in the Georgian Medical Journal.
Journal website:
https://gmj.ge/index.php/pub/index
#გიორგიფხაკაძე #drpkhakadze #sheniekimi